Keywords: Neurim Pharma, Piromelatine, Insomnia, Ph II
Neurim Pharma's piromelatine insomnia drug candidate does well in Ph II
Article | 18 February 2013
Israel-based Neurim Pharmaceuticals has announced positive results from a Phase II study evaluating the efficacy and safety of piromelatine (Neu-P11), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
